Phase 3
Completed N=210
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Source: ClinicalTrials.gov NCT00577993 ↗Enrolled (actual)
210
Serious AEs
91.1%
Results posted
Nov 2020
Primary outcomePrimary: Number of Participants With Overall Survival (10 Years) by Treatment — 59; 58 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Overall Survival (10 Years) by Treatment |
59; 58 | — |
| SECONDARY Number of Participants With Progression Free Survival (10 Years) by Treatment |
59; 58 | — |
Eligibility Criteria
Inclusion Criteria
- Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001: eligibility restricted to follicular lymphoma]
- Age <76
Exclusion Criteria
N/A
Data sourced from ClinicalTrials.gov (NCT00577993). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.